On Aug. 7, 2020, Altimmune announced that it had completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate.

NasoShield has the potential to be a convenient and simple alternative to the current approved multi-dose anthrax vaccine.